Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19

Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19

Type 2 diabetes mellitus (T2DM) is a potential risk factor for the development of COVID-19 and is associated with higher severity and mortality rates. T2DM patients are commonly treated with metformin monotherapy or metformin plus sitagliptin. In the present case-control, single-center cohort study,...

Full description

Bibliographic Details
Main Authors: Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Sarah M. Albogami, Sabatier Jean-Marc, Eman Hassan Nadwa, Amin A. Hafiz, Walaa A. Negm, Marwa Kamal, Mohammed Al-Jouboury, Engy Elekhnawy, Gaber El-Saber Batiha, Michel De Waard
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Pharmaceuticals
Subjects:
cytokines
diabetes mellitus
metformin
SARS-CoV-2
sitagliptin
Online Access:https://www.mdpi.com/1424-8247/15/11/1361

Similar Items

Similar Items